What is NAD+ and why does it matter for cellular health?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It works in two distinct roles. First, it shuttles electrons through the metabolic reactions that produce ATP—the fuel your cells run on. Second, it is consumed as a substrate by enzyme families including sirtuins, PARPs, and CD38, each of which uses NAD+ to regulate processes ranging from DNA repair to circadian rhythm.
The reason clinicians and researchers pay attention to NAD+ is that its intracellular pool shrinks with age. Published data from human tissue samples show meaningful NAD+ decline across multiple organ systems beginning in mid-adulthood, with accelerating loss in later decades. Because NAD+ is required for both energy metabolism and damage-repair signaling, a smaller pool means less throughput in both.
What drives NAD+ decline with age?
Three mechanisms account for most of the age-related drop. CD38, an enzyme expressed by immune cells, is the primary culprit: its expression rises with age and chronic inflammation, and it is an extremely efficient NAD+ consumer. PARPenzymes activated by cumulative DNA damage are a second drain. And biosynthesis—the body’s internal production from dietary precursors like tryptophan and niacin—becomes less efficient over time.
The net result is that older adults are running cellular energy and repair machinery on a smaller substrate pool than they had at twenty or thirty. NAD+ therapy is designed to address that gap.
Direct repletion by injection or infusion raises NAD+ more efficiently than oral NMN or NR — which is the whole pharmacokinetic case for NAD+ therapy.
How is NAD+ therapy administered?
There are two main routes in clinician-supervised settings. Intravenous infusion delivers NAD+ directly into the bloodstream, bypassing the digestive tract entirely. It produces the fastest rise in circulating NAD+ but requires sitting for a multi-hour infusion and is typically done in a clinical setting. High infusion rates can cause transient flushing, chest tightness, or nausea; slowing the rate usually resolves these.
Subcutaneous injection is the route most commonly used in telehealth protocols. A small-gauge needle delivers compounded NAD+ into the tissue just under the skin, where it is absorbed into systemic circulation. Self-administration is practical after clinician instruction. This approach supports consistent dosing on a schedule without requiring clinic visits for every dose.
In both cases, the NAD+ is compounded by licensed US 503A pharmacies— custom-formulated for the individual patient, not mass-manufactured. That distinction matters: compounded NAD+ is not an FDA-approved drug, and PepScribe does not represent it as one. What it is: a personalized preparation from licensed compounders with no hidden overseas supply chain.
What does the evidence say about NAD+ therapy?
Human evidence on NAD+ supplementation is more developed than it is for most peptides discussed in wellness contexts, though it is still early relative to what a complete clinical picture would require. Several key findings:
- NAD+ precursors raise tissue levels. Human trials using NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) have demonstrated measurable increases in blood and tissue NAD+ levels at clinical doses. Direct NAD+ administration achieves a larger and faster rise.
- Sirtuin activation follows NAD+ availability. The sirtuin enzymes that regulate mitochondrial biogenesis, inflammatory signaling, and DNA repair are NAD+-dependent. Preclinical and some human data show that raising NAD+ can restore sirtuin activity that had declined with age.
- Mitochondrial function is sensitive to NAD+ pool size. The 2013 Cell paper by Gomes and colleagues demonstrated in animal models that restoring NAD+ reversed age-associated disruptions in nuclear-mitochondrial communication. Human studies exploring analogous effects are underway.
- Human safety profile is acceptable at clinical doses. Published human studies and clinical use data do not show serious adverse effects at doses used in supervised protocols. The most consistent adverse effects are infusion-related and transient.
What the evidence does not yet support: specific clinical outcome claims in healthy humans at defined doses. The trajectory of the research is promising, but honest clinicians frame NAD+ therapy as supporting biological processes that decline with age, not as a treatment for specific diseases or a guarantee of particular results.
Who typically uses NAD+ therapy, and why?
Clinicians who prescribe NAD+ therapy tend to work with several overlapping patient profiles. Adults in their forties and above noticing energy decline that does not resolve with adequate sleep and nutrition often explore NAD+ as part of a longevity or cellular health protocol. Athletes and active adults interested in recovery optimization make up another group. Individuals with cognitive concerns—brain fog, word retrieval, sustained attention—sometimes pursue NAD+ because of the coenzyme’s role in neuronal energy metabolism.
None of these use cases carry a disease-treatment claim. NAD+ therapy is positioned as support for cellular processes that are measurably compromised by aging, not as a medical cure. The distinction matters legally and, more importantly, it matters for setting accurate patient expectations.
How is a clinician-supervised NAD+ protocol structured?
A well-structured protocol begins with a clinician intake. The clinician reviews health history, current medications, and the patient’s specific goals. Where appropriate, baseline labs—including relevant biomarkers—give the clinician a pre-treatment reference point.
Dosing is individualized. Starting doses for subcutaneous protocols are typically conservative, with titration based on patient response during early check-ins. The compounding pharmacy compounds to the prescribed dose, not a one-size-fits-all batch.
Follow-up is built into the protocol. Changes in energy, sleep quality, cognitive function, and recovery are tracked against the baseline. Labs may be repeated at intervals to monitor NAD+ levels and ensure the protocol is working as intended. If the clinical picture doesn’t support continuing, the clinician will say so.
This is the difference between supervised NAD+ therapy and buying an OTC NR supplement: the former involves actual clinical oversight, personalized dosing, and accountability. The latter does not.
Frequently asked questions about NAD+ therapy
What is NAD+ therapy?
NAD+ therapy refers to clinician-supervised supplementation designed to support the body's intracellular levels of nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy production, DNA repair, and sirtuin activation. Administration routes include subcutaneous injection and intravenous infusion, both compounded by licensed 503A pharmacies.
Does NAD+ therapy work?
Human research on NAD+ supplementation is early but growing. Studies show that precursor supplementation (NMN, NR) and direct NAD+ administration can raise circulating and tissue NAD+ levels. Whether that translates to specific clinical outcomes depends on the individual, their baseline NAD+ status, and the protocol used. Outcomes are assessed with clinician check-ins and labs, not assumed in advance.
Is NAD+ therapy safe?
NAD+ compounded by licensed US 503A pharmacies has a favorable safety profile in clinical use. Common transient effects during IV infusion include flushing and chest tightness at higher infusion rates; subcutaneous protocols generally have fewer acute effects. A clinician evaluation before starting is standard practice.
How is NAD+ therapy administered?
The two main routes are intravenous (IV) infusion, which delivers NAD+ directly into the bloodstream, and subcutaneous injection, which is self-administered at home after clinician instruction. Subcutaneous protocols are common in telehealth settings because they do not require a clinical facility for each dose.
Who is a candidate for NAD+ therapy?
Clinicians typically consider NAD+ therapy for adults experiencing energy decline, cognitive fog, post-exertion recovery concerns, or those interested in longevity protocols. A licensed clinician assesses medical history, current medications, and goals before recommending a protocol. NAD+ is not appropriate for everyone.
How long does it take to see results from NAD+ therapy?
Responses vary. Some patients report energy and cognitive changes within the first few weeks of a subcutaneous protocol; others notice changes more gradually over one to three months. No specific timeline can be guaranteed because individual NAD+ metabolism, baseline deficiency, and dosing all vary.